Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Nov 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-11-03

Reporting Person: Sommadossi Jean-Pierre (Director, President, CEO, and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-03	Common Stock	C	750000	—	Acquired	5925000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-03	Series A Convertible Preferred Stock	$	C	750000	Disposed		Common Stock (750000)	Indirect

Footnotes

F1: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.